Summary PTEN, a putative tumour suppressor gene associated with prostate and other cancers, is known to be located within the chromosomal region 10q23.3. Transcription of the PTEN gives rise to multiple mRNA species. Analyses by Northern blots, using cell lines which express PTEN together with cell lines which have lost the PTEN or carry a truncated version of the gene, has allowed us to demonstrate that the pseudogene is not transcribed. In addition, 3′ RACE studies confirmed that the multiple mRNA species arising from the gene probably result from the use of alternative polyadenylation sites. No evidence for tissue-or cell-specific patterns of transcription was found. Analysis by 5′ RACE placed the putative site for the start of transcription around 830 bp upstream of the start codon. A map of the location of the PTEN gene with a series of overlapping YAC, BAC and PACs has been constructed and the relative position of eight microsatellite markers sited. Two known and one novel marker have been positioned within the gene, the others are in flanking regions. The more accurate location of these markers should help in future studies of the extent of gene loss. Several polymorphisms were also identified, all were within introns. Four of the common polymorphisms appear to be linked. In blood, DNA from 200 individuals, including normal, BPH and prostate cancer patients, confirmed this link. Only two samples of 200 did not carry the linked haplotype, both were patients with advanced prostate cancer. It is possible that such rearrangements within PTEN could be evidence of predisposition to prostate cancer in this small number of cases.
Allelic loss at the chromosomal region 10q23-25 has been reported for prostate and several other cancers (Gray et al, 1995; Bose et al, 1998; Cairns et al, 1998; Feilotter et al, 1998; Maier et al, 1998; Robertson et al, 1998) . Analysis of loss of heterozygosity (LOH) in microdissected prostate tumours initially placed the minimum region of loss between the markers D10S1644 (AFMa124wd9) and D10S583 (Gray et al, 1998) and was subsequently refined to a region of 400 kb between D10S1765 and D10S541 (Gray, unpublished data) . A putative tumour suppressor gene called PTEN, MMAC1 or TEP1 (Li and Sun, 1997; Steck et al, 1997) has been located within this region and was mutated in glioblastomas, endometrial and prostate tumours (Cairns et al, 1997; Rasheed et al, 1997; Tashiro et al, 1997; Feilotter et al, 1998; Gray et al, 1998) . In addition, germline PTEN mutations have been found to be associated with Cowden's disease and related syndromes such as Bannayan-Zonana syndrome .
PTEN has regions of homology to chicken tensin and auxilin and incorporates phosphatase domains which are active against both lipid and protein substrates (Myers et al, 1997; Maehama and Dixon, 1998) . Evidence for a tumour suppressor function for PTEN comes from experiments in which transfection of PTEN into a medulloblastoma cell line null for PTEN expression caused inhibition of proliferation and anchorage-dependent growth (Cheney et al, 1998) . Total gene disruption resulted in embryonic lethality in mice, whereas animals heterozygous for PTEN expression showed hyperplasticdysplastic changes in epithelial tissues and an increased incidence of tumours (Di Cristofano et al, 1998) . The tumour suppressor activity of PTEN may result from its demonstrated ability to dephosphorylate the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), thereby restricting cell growth and allowing apoptosis to occur (Maehama and Dixon, 1998; Tamura et al, 1998) . In addition, the ability of PTEN to dephosphorylate focal adhesion kinase may prevent cell migration (Tamura et al, 1999) , and the inactivation of PTEN has recently been associated with increased angiogenesis in prostate carcinomas (Giri and Ittmann, 1999) .
Analysis of the PTEN mRNA species has revealed a complex pattern of different sized transcripts Gray et al, 1998) some of which could have arisen from alternate splice events. Additionally a pseudogene for PTEN (ψ PTEN) has been identified on chromosome 9 which has been claimed to be transcribed (Dahia et al, 1998) . In this paper we investigate origins of the major mRNA species seen on Northern blots and describe BAC/PAC coverage of the region along with the exact location of several polymorphic markers and identification of single nucleotide polymorphisms. 
MATERIALS AND METHODS

YAC, BAC and PAC isolation
YAC 821D2 was identified from the CEPH Mega YAC library by using the 'infoclone' program (Chumakov et al, 1995) to screen for YACs bearing CA repeat markers spanning the minimal region and a clone obtained from the UK HGMP Resource Centre in Cambridge. BAC and PAC clones were identified from Human BAC pools and RPCI Human PAC libraries (Research Genetics) by polymerare chain reaction (PCR) screening with CA repeat markers. BAC146B18 was isolated as a clone from which we could amplify the T7 (telomeric) end of BAC46B12 and whose centromeric end sequence could be amplified from BAC122L22. Insert size was estimated by restriction enzyme digests using infrequently cutting restriction endonucleases, followed by separation by pulsed field gel electrophoresis using manufacturer's recomended conditions (BioRad).
Cell lines
The lymphoblastoid line Bristol 8 (BRI8) has been previously described (Gray et al, 1998) , DU145, PC3 and A172 were from ATCC, and UMUC3 was provided by Prof. M Knowles (Aveyard et al, 1998) . A second vial of DU145 was obtained from Dr R Schrock (Introgen Therapeutics Inc.). All lines were grown in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% fetal calf serum.
Exon, intron and microsatellite marker amplification
Exons were amplified as previously described (Gray et al, 1998) using primers based on intronic sequences. Primer sequences for Chemical Cleavage of Mismatches (CCM) were obtained from BAC sequence data obtained within the laboratory, and the 5′ end of each 3′ primer was PIG-tailed to facilitate CCM (Brownstein et al, 1996) . CCM cycling conditions were as follows: 10 min at 96°C followed by 35 cycles of 96°C for 30 s, 49-60°C for 30 s, 72°C for 5 min in a Perkin-Elmer 9600 thermal cycler and using Taq Gold (Perkin-Elmer). Annealing temperature was dependent on primer pair used.
BAC sequencing
BACs were prepared using a modified Qiagen midi prep method. Two hundred millilitres cultures were grown in selective medium and processed by the Qiagen midi prep protocol, except that 15 ml of P1, P2 and P3 were used in place of the recommended 4 ml. After centrifugation DNA was precipitated from the supernatant with isopropanol, the pellet washed with 70% ethanol and resuspended in 1 ml of dH 2 O (heavy water) and 0.25 ml of 10 M NH 4 Ac. Non-soluble particles were removed by centrifugation and DNA was ethanol precipitated. After centrifugation, the pellet was redissolved in 2 ml of H 2 O and 10 ml of QBT buffer. Qiagen protocols were followed thereafter. The DNA was finally resuspended in a total of 120 µl, and 6-8 µl used per sequence reaction. DNA sequence reactions were performed using Big Dye Terminator Cycle Sequencing Ready Reaction Kits (PerkinElmer) and analysed on an ABI377.
Chemical cleavage of mismatches
CCM in heteroduplexes formed between two different alleles was performed using the hydroxylamine method (Rowley et al, 1995) . The reaction products were analysed on a 6% acrylamide/urea gel with 12-cm plates at 950 volts for 3.5-4 h on an ABI 377 DNA sequencer. The results were analysed using Genescan 2.1.1 software. When cleavage products were detected, PCR products spanning the relevant interval were purified using Qiagen PCR cleanup columns and sequenced using the amplification primers to determine the exact nature of the mismatch.
5′-and 3′-rapid amplification of cDNA ends (RACE)
5′-and 3′-RACE reactions were performed using 0.1-0.2 ng of Marathon-Ready prostate cDNA (Clontech) and Advantage-GC cDNA PCR buffer and polymerase mix (Clontech). PCR reactions were carried out in a 9700 thermal cycler (Perkin-Elmer) in a total volume of 50 µl. Cycling parameters for 5′-RACE were either 94°C for 1 min followed by 35 cycles of denaturation for 30 s and extension for 3 min at 68°C or 'touchdown' PCR where a 30 s denaturation step was followed by 5 cycles of 94°C for 10 s and 72°C for 4 min, 5 cycles of 94°C for 10 s and 70°C for 4 min and 25 cycles of 94°C for 10 s and 67°C for 4 min. When touchdown PCR conditions were used for the primary PCR, the nested PCR parameters were denaturation for 30 s followed by 5 cycles of 94°C for 10 s, 62°C for 30 s, 68°C for 2 min, 5 cycles of 94°C for 10 s, 60°C for 30 s, 68°C for 2 min and 25 cycles of 94°C for 10 s, 59°C for 30 s, 68°C for 2 min. The following primers were used in the primary 5′-RACE reactions: GSP1, 5′-GGCAGAA-GCTGCTGGTGGCGGGG; GSP2, 5′-GCCGCCGTGTTGGAG-GCAGTAGAAGGGG; GSP3, 5′-AACTGAGCGCAGTCGCGT-CCCAGCGC and AP1 (Clontech). In the nested 5′-RACE reactions the primers were NGSP1, 5′-GGAAATGGCTCTG-GACTTGGCGG; NGSP2,5′-ACCAACTCTCCGGCGTTCCC-AGC; NGSP3, 5′-CAGCGCATAAAGAGTCCTGCCAC and AP2 (Clontech). Cycling parameters for 3′-RACE were 94°C for 1 min followed by 6 cycles of 94°C for 10 s and 67°C for 3 min and 30 cycles of 94°C for 10 s and 64°C for 4 min. The following primers were used in the 3′-RACE reactions in combination with the AP1 and AP2 primers from Clontech: 3′GSP2, 5′-CATC-CACAGGGTTTTGACAC; 3′NGSP2, 5′-GGTTGTGTAGCTGT-GTCATG; 3′GSP3, 5′-CGGGTTAGGGCAATGGAGGGGAA-TGC; 3′NGSP3, 5′-CGAGGAATTGGCCGCTGTCACTGC. The RACE products were gel purified (Qiagen) and cloned into pGEM-T Easy Vector (Promega) or sequenced directly.
RNA and Northern analysis
Messenger RNA was extracted from the cell lines UMUC3, BRI8, DU145 and A172 using FastTrack RNA isolation kit (Invitrogen). Five micrograms of mRNA from each cell line were size-fractionated on a 1% formaldehyde agarose gel and transferred to a Hybond N + membrane (Amersham) using 20 × SSC (sodium-saline citrate) as transfer buffer. A full length PTEN cDNA probe was labelled with 32 P-dCTP using Megaprime DNA labelling system (Amersham). A probe fragment was generated for the 3′UTR region by PCR using primers 5′-GACTGAAAG-GTTTTCGAGTCC and 5′-GAGGAGCTACAAAGGACTTGG and labelled with 32 P-dCTP as described previously (Gray et al, 1998) . RNA hybridization was carried out using ExpressHyb hybridization solution (Clontech) according to the manufacturer's instructions. Membranes were washed in 2 × SSC and 0.1% sodium dodecyl sulphate (SDS) at room temperature for 50 min with several changes of wash solution. X-ray film (Fuji) was exposed to the Northern blots in the presence of 2 screens for 1-3 days.
RESULTS
LOH of the chromosomal region around PTEN occurs in several cancer types, and to allow a more detailed analysis of this loss a map of overlapping BACs and PACs was constructed and several microsatellite markers positioned on this map along with the exons/introns of PTEN ( Table 1 ). The PTEN gene covers approximately 100 kb and the markers D10S2491 and D10S1765 which are located 5′ or telomeric to the gene were found to be identical. D10S608 which has previously been used to map PTEN LOH is not located within the designated region and is at least 160 kb telomeric of the PTEN gene. Markers AFMa086wg9 (intron 2) and D10S2492 (intron 8) are located within PTEN. In addition a further CA repeat was identified from sequencing within intron 8 which was heterozygous in 45% of a sample of blood DNAs from a group of 200 individuals when these were analysed by microsatellite methods.
Comparison of genomic and BAC sequencing with database sequences for intron 1 (Genebank sequence -BAC 265N13) showed that there was probably a deletion in the database submission. Genomic sequences we have obtained from around PTEN have been lodged with Genbank (Accession Nos AF143312, AF143313, AF143314, AF143315, AF143316, AF143317 and AF143318).
In addition to microsatellite markers a search for single nucleotide polymorphisms was undertaken. PTEN intronic sequence primers were used to PCR amplify 1-1.5 kb fragments of DNA from 20 normal human blood samples. PTEN regions amplified included 1.9 kb downstream of exon 3, approximately 6.7 kb upstream of exon 4, all of intron 4, 1.5 kb downstream of exon 5, and 1 kb downstream of exon 6. These fragments, which covered around 12 kb of sequence in total, were analysed by CCM to identify polymorphisms and potential changes were confirmed by sequencing. Polymorphisms and levels of heterozygosity are listed in Table 2 ; some of these polymorphisms have been described previously but confirmed by CCM and sequencing during the course of our studies.
Four polymorphic markers located within the PTEN gene had a similar frequency of heterozygosity of around 40% and were used to analyse the DNA obtained from the blood of 200 individuals (these included 97 prostate cancer patients, 43 patients with benign prostatic hyperplasia and 60 other non-cancer patients). From this analysis it appeared that two distinct haplotypes existed. For the four markers 1, 4, 5 and 8 respectively (Table 2), the linkage was either G,A,+,G or A,G,-,T. Of the 200 DNAs tested, 45.5% were heterozygous at each of the markers, 12% were homozygous for A,G,-,T haplotype and 41.5% were homozygous for G,A,+,G haplotype. Only two out of 200 individuals did not carry the linked haplotype in their blood DNA and both were cancer patients, their genotypes were A,G,-,G/T and A,G/A,+/-,G/T.
To analyse the complex pattern of transcription found for PTEN a number of cell lines were studied. Five cell lines were analysed by PCR for the presence or absence of PTEN and ψPTEN. To distinguish PTEN from ψPTEN, primers complementary to intron sequences were used to amplify PTEN exons (ψPTEN is processed and has no introns). In cell lines where all nine PTEN exons were present these exons were sequenced. The B lymphoblastoid cell line BRI8 and the prostate line DU145 contained all PTEN exons and carried no mutations. DU145 has been described as carrying a mutation at codon 145 ; we were unable to find this mutation in two independent sources of DU145. Consistent with published results the glioblastoma cell line A172 contains only exons 1 and 2, and the bladder cell line UMUC3 has lost all PTEN exons Steck et al, 1997; Aveyard et al, 1998) . PC3 cells used for these studies contained only exons 1 and 2. The presence of the PTEN pseudogene in these cell lines was determined using PCR primers from the boundary of exons 3 and 4 and from exon 6, which could only generate a product when no intronic sequences were present. PTEN pseudogene sequences were found to be present in all cell lines examined. Multiple PTEN transcripts Gray et al, 1998) were evident in BRI8 and DU145 cells, but no mRNA transcripts were detected in UMUC3 cells which were null for PTEN but positive for the ψPTEN. A shortened transcript was detected in the mRNA from the A172 cell line which has only exons 1 and 2 (Figure 1 ). Black squares indicate the presence and white squares the absence of the marker or exon. Primers used for the amplification of the exons can be found in the Genome Database (http://www.GDB.org) with the exception of CA8/9 which was amplified using the primer pair 5′-CAGCACTTTGG-GAGGCTAAG/5′-TTTCACTTAAAACGTGCAGGGG. B146B18 overlaps B122L22 and B60C5 but does not contain a marker or exon.
Previously we reported that a 121 bp probe from position 338 to 459 upstream of the ATG start codon of PTEN hybridized to a single transcript on Northern blots (Gray et al, 1998) , which could be evidence of alternate splicing. However, when this probe was used on a Northern blot containing mRNA from BRI8, DU145, UMUC3 and A172 cells a band of approximately 5.5 kb was detected in cell lines that are both positive and negative for PTEN. Exact alignment of Northern blots showed that this band was marginally smaller than the expected 5.5 kb transcript detected with a PTEN exon 1 probe (data not shown; Gray et al, 1998) .
3′-RACE was employed to confirm the use of alternate polyadenylation sites, which would give rise to multiple transcripts, and extension of transcription beyond the end of the published MMAC1 sequence (GenBank accession U92436). 3′-RACE products generated using primers 3′NGSP2 (located 204 bp downstream of the PTEN stop codon) and AP2 terminated with poly-adenosine (poly-A) tails either 290-300 bp downstream from the stop codon and within 20-40 bp of two AAUAAA elements, or where the published MMAC1 sequence terminates 910 bp from the stop codon (data not shown). 3′-RACE products produced using the primers 3′NGSP3 and AP2 terminated in the vicinity of the end of the MMAC1 sequence with a poly-A tail. Longer 3′-RACE products were not generated with the conditions used. However, while this work was in progress a search of the GenBank database revealed one EST, IMAGE clone 361374 (Accession Nos AA017563 and AA017584), which extended 271 bp downstream of the end of the MMAC1 sequence, indicating that transcription can progress beyond the end of the MMAC1 sequence. Furthermore, a probe from the 3′ untranslated region located 2471-2680 bp downstream of the termination codon, and prior to a group of polyadenylation signals in the genomic sequence, gave a single band on Northern blots equivalent to the largest mRNA species (Figure 2) , providing further evidence for transcription extension.
To identify the putative transcription start site and to explore the possibility that long PTEN transcripts may result from alternate splicing involving novel 5′ exons, 5′ RACE was performed using three sets of nested primers: GSP1 + NGSP1, GSP2 + NGSP2, GSP3 + NGSP3. The PCR primer set GSP3 + NGSP3, located 860 nt upstream of the longest published cDNA sequence (Li and Sun, 1997) , did not result in a PCR product suggesting the coding sequence does not extend into this region. Several PCR fragments were generated using GSP1 + NGSP1 and GSP2 + NGSP2 which displayed sequence identity with previously published sequence (Li and Sun, 1997) . The largest fragment extended 827 bp in the 5′ direction from the start codon, 35 bp further than the TEP1 cDNA sequence. A second fragment also finished at this point while a third finished 824 bp from the start codon.
DISCUSSION
The PTEN gene covers over 100 kb of a 400 kb region of allelic loss common to most prostate tumours (Gray et al, 1995) . Although the detection frequency of PTEN mutations in prostate tumours is lower than anticipated (Cairns et al, 1997; Teng et al, 1997; Feilotter et al, 1998; Gray et al, 1998) , the frequency of mutations in other tumour types such as glioblastoma and endometrial carcinoma Rasheed et al, 1997; Tashiro et al, 1997; Teng et al, 1997; Duerr et al, 1998; Risinger et al, 1998) , taken together with the data from in vitro cell growth experiments and the targeted disruption of PTEN in mice (Di Cristofano et al, 1998) , support the view that PTEN is a tumour suppressor gene. We have mapped CA repeat markers D10S608, AFMa086wg9, D10S2491 and D10S2492 precisely around PTEN and identified a number of other common intragenic polymorphisms including a novel CA repeat within intron 8 of PTEN. These polymorphisms could prove useful for future studies on PTEN and will provide a panel of markers for more detailed mapping of LOH. We have also identified the existence, within the population, of two distinct haplotypes covering this region, although no polymorphisms were found within the coding sequence of PTEN.
We have attempted to dissect the complex PTEN mRNA transcript profile. Two cell lines, UMUC3 and A172, were used to determine whether a known pseudogene on 9p21 (Dahia et al, 1998) contributes to the pattern of PTEN mRNA transcripts. Both cell lines retain the pseudogene but UMUC3 has completely lost both copies of the PTEN gene and A172 retains exons 1 and 2 of PTEN. On Northern blot analysis no transcript was identified for UMUC3 and an altered message profile was found in A172 cells consistent with the truncated copy of PTEN present in this cell line. These results indicate that the pseudogene is not transcribed and does not contribute to any of the transcripts identified in cell lines studied. The pseudogene was originally identified by cloning from RT-PCR implying that transcription was taking place (Kim et al, 1998) and has subsequently been reported as occurring as a major mRNA species (Fujii et al, 1999 ). Although we cannot exclude the possibility that there could be some cell/tissue-specific transcription of the pseudogene, the similarity of the multiple species seen on Northern blots with mRNA from a variety of different tissues (Gray et al, 1998 ) and the PTEN-positive cell lines described here, taken together with data described by others (Dahia et al, 1998) makes it appear more likely that the pseudogene is not transcribed.
We previously reported that a probe derived from the 5′ sequence of PTEN detects only a 5.5 kb transcript whereas full length cDNA probes or probes derived from individual exons all give a complex pattern with major RNA species at 2.1 kb, 2.4 kb and 5.5 kb (Gray et al, 1998) . When this probe was used to analyse RNA from PTEN null cells a single band was seen in both UMUC3 and A172 which was identical to the pattern seen for PTEN-expressing cells. Therefore this 5.5 kb band is distinct from the similarly sized transcript detected with probes derived from the PTEN coding region. Consequently it is unlikely to have arisen from alternate PTEN splicing and is more likely to be the result of cross-hybridization to an unrelated RNA with some sequence similarity to the PTEN 5′ UTR.
Published cDNA sequence of the PTEN 5′ UTR extends 790 bp upstream of the ATG translation start site. To determine the region of initiation of transcription a commercial prostate cDNA library was analysed by 5′-RACE. The clones obtained extend the longest previously reported cDNA sequence (Li and Sun, 1997) by 38 bases. Primers derived from genomic sequence 5′ to this region and 5′ to the published TEP1 cDNA sequence did not produce a PCR product. This suggests that the transcription start site is in the region of the sequence described by Li and Sun (1997) , which would give a 5′ untranslated sequence of around 827 bp, with a gene sequence of 1209 bp and the first polyadenylation sites at 60 bp and 290 bp from the translation termination signal. These distances correlate with the size of the smaller mRNA species of 2.1 and 2.4 kb seen on Northern analysis (Gray et al, 1998) . The larger 5.5 kb species is likely to result from a further polyadenylation site approximately 3 kb downstream of the second polyadenylation signal. This conclusion is supported by Northern blot analysis where the 5.5 kb mRNA species was identified with a probe from a region 3 kb downstream of the termination codon (Gray et al, 1998) . cDNA sequences in the database and 3′ RACE experiments confirm that alternative polyadenylation sites are used and that poly-A tails are added at the equivalent position to the 2.1 and 2.4 kb and that longer species are also transcribed. This analysis taken in conjunction with the analysis of PTEN null and PTEN truncated cell lines suggests that the complex pattern of mRNAs seen on Northern blots arises largely from alternative polyadenylation sites and that no major contribution to this pattern is made by pseudogene transcription, alternate splicing or crosshybridization to related gene family members. The significance of the variable 3′ UT sequences is unclear but regulatory elements in this region in other genes have been associated with cell differentiation (Rastinejad and Blau, 1993) , mRNA stability particularly in cancer cells (Rajagopalan and Malter, 1997) and tissue-specific expression (Coy et al, 1999 ).
PTEN appears to be an important tumour suppressor gene which is lost in many cancers. In some cases, particularly in glioblastomas and endometrial cancers, the presence of LOH and mutations in the second gene is consistent with the Knudson two-hit hypothesis (Knudson, 1991) . In the case of prostate cancer, LOH is common (Gray et al, 1995) but mutations in the remaining gene are rare (Gray et al, 1998) , although loss of transcription due to methylation has been reported in some tumour samples (Whang et al, 1998) . The detailed genomic map and an analysis of PTEN transcripts should assist in the understanding of the genomic changes which contribute to tumour progression by the inactivation of PTEN in prostate and other tumours.
